Volume : 08, Issue : 12, December – 2021
Title:
38.REVIEW ON MUCORMYCOSIS
Authors :
Mrs. Savitha Mol G M*, Mrs. Aswathy S S, Mrs. Remya S B, Mrs. Aparna P, Dr. Silvia Navis A, Dr. Prasobh G R
Abstract :
Mucormycosis is the third invasive mycosis in order of importance after candidiasis and aspergillosis and is caused by fungi of the class Zygomycetes. The most important species in order of frequency is Rhizopus arrhizus (oryzae). Identification of the agents responsible for mucormycosis is based on macroscopic and microscopic morphological criteria, carbohydrate assimilation and the maximum temperature compatible with its growth. The incidence of mucormycosis is approximately 1.7 cases per1000000 inhabitants per year, and the main risk-factors for the development of mucormycosis are ketoacidosis (diabetic or other), iatrogenic immunosuppression, use of corticosteroids or deferoxamine, disruption of mucocutaneous barriers by catheters and other devices, and exposure to bandages contaminated by these fungi.
The standard guidelines in management of mucormycosis involves early diagnosis, a reversing risk factors and underlying illness, surgical debridement, and immediate intravenous antifungals – usually amphotericin B. This include the prompt management of hyperglycaemia, acidosis, electrolyte imbalance and cessation of immunosuppressive drugs.
Cite This Article:
Please cite this article in press Savitha Mol G M et al, Review On Mucormycosis, Indo Am. J. P. Sci, 2021; 08(12).
Number of Downloads : 10
References:
1. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect, 2004; 10(1): 31–47.
2. Randhawa HS, Budimulja U, Bazaz-Malik G, Bramono K, Hiruma M, Kullavanijaya P, Rojanavanich V. 1994. Recent developments in the diagnosis and treatment of subcutaneous mycoses. Med Mycol 32: 299–307.
3. Waldorf AR. Pulmonary defense mechanisms against opportunistic fungal pathogens. Immunol Ser., 1989; 47: 243–271.
4. Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest, 1984; 74: 150–160.
5. Song WK, Park HJ, Cinn YW, Rheem I, Pai H, Shin JH. Primary cutaneous mucormycosis in a trauma patient. J Dermatol 1999; 26: 825–828.
6. Hotchi M, Okada M, Nasu T. Present state of fungal infections in autopsy cases in Japan. Am J Clin Pathol 1980; 74: 410–416.
7. Tietz HJ, Brehmer D, Janisch W, Martin H. Incidence of endomycoses in the autopsy material of the Berlin Charite Hospital. Mycoses 1998; 41 (suppl 2): 81–85.
8. Yamazaki T, Kume H, Murase S, Yamashita E, Arisawa M. Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol 1999; 37: 1732–1738.
9. Waldorf AR. Pulmonary defense mechanisms against opportunistic fungal pathogens. Immunol Ser 1989; 47: 243–271. 33. Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest 1984; 74: 150–160.
10. Diamond RD, Haudenschild CC, Erickson NF 3rd. Monocyte-mediated damage to Rhizopus oryzae hyphae in vitro. Infect Immun 1982; 38: 292–297.
11. Chinn RY, Diamond RD. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect Immun 1982; 38: 1123–1129.
12. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18: 556–569.
13. . Lehrer RI, Howard DH. Mucormycosis. Ann Intern Med 1980; 93: 93–108.
14. Bigby TD, Serota ML, Tierney LM Jr, Matthay MA. Clinical spectrum of pulmonary mucormycosis. Chest 1986; 89: 435–439.
15. Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. Arch Intern Med 1999; 159: 1301–1309.
16. Dobrilovic N, Wait MA. Pulmonary mucormycosis. Ann Thorac Surg 2005; 79: 354.
17. Funada H, Matsuda T. Pulmonary mucormycosis in a hematology ward. Intern Med 1996; 35: 540–544.
18. Diamond RD, Haudenschild CC, Erickson NF 3rd. Monocyte-mediated damage to Rhizopus oryzae hyphae in vitro. Infect Immun, 1982; 38: 292–297.
19. Boelaert JR, de Locht M, Van Cutsem J et al. Mucormycosis during deferoxamine therapy is a siderophoremediated infection. In vitro and in vivo animal studies. J Clin Invest, 1993; 91: 1979–1986.
20. Nosari A, Oreste P, Montillo M et al. Mucormycosis in hematologic malignancies: an emerging fungal infection. Haematologica 2000; 85: 1068–1071.
21. Jimenez C, Lumbreras C, Aguado JM et al. Successful treatment of mucor infection after liver or pancreas–kidney transplantation. Transplantation 2002; 73: 476–480.
22. Nampoory MR, Khan ZU, Johny KV et al. Invasive fungal infections in renal transplant recipients. J Infect 1996; 33: 95–101.
23. Morduchowicz G, Shmueli D, Shapira Z et al. Rhinocerebral mucormycosis in renal transplant recipients: report of three cases and review of the literature. Rev Infect Dis 1986; 8: 441–446.
24. Sehgal A, Raghavendran M, Kumar D, Srivastava A, Dubey D, Kumar A. Rhinocerebral mucormycosis causing basilar artery aneurysm with concomitant fungal colonic perforation in renal allograft recipient: a case report. Transplantation 2004; 78: 949–950.
25. Quinio D, Karam A, Leroy JP et al. Zygomycosis caused by Cunninghamella bertholletiae in a kidney transplant recipient. Med Mycol 2004; 42: 177–180.